Microbot Medical Expands Global Patent Portfolio to Strengthen Protection of LIBERTY Robotic Surgical Technology
Microbot Medical, a medical technology company developing and distributing the LIBERTY® Endovascular Robotic System, has announced another development in its global intellectual property strategy. The company confirmed that the Canadian Intellectual Property Office (CIPO) has granted it a patent covering an adaptor designed to connect a surgical tool to a motorized robotic surgical device. The patent represents an additional step in Microbot Medical’s efforts to protect the technology and engineering features supporting its robotic platform.
The newly granted patent relates to an adaptor used to couple the proximal portion of an elongated surgical tool, such as a guidewire or microcatheter, to a motorized robotic surgical device. These instruments are used in endovascular procedures, where physicians navigate through blood vessels to reach specific treatment areas. The adaptor is intended to provide the connection between the surgical instrument and the robotic system, forming part of the technology that enables robotic operation.
With this latest Canadian patent, Microbot Medical reports that its global intellectual property portfolio includes 45 issued patents and 48 patent applications worldwide. The company also holds 21 issued patents in North America. These figures reflect its continuing efforts to establish legal protection for the distinctive features and technical characteristics of the LIBERTY Endovascular Robotic System as it develops its commercial strategy.
Strengthening Protection for the LIBERTY Endovascular Robotic System
The LIBERTY Endovascular Robotic System is the central technology behind Microbot Medical’s development and commercialization efforts. The system is designed for peripheral endovascular procedures and enables physicians to operate instruments remotely through a robotic platform. Its technology is intended to support precise navigation within the vascular system while addressing certain physical challenges associated with traditional endovascular procedures.
The newly granted patent is relevant to the mechanical and functional components that connect surgical instruments with robotic devices. In robotic-assisted procedures, the ability to securely and effectively couple instruments to the robotic platform is an important part of the overall system design. The adaptor described in the patent addresses this connection between the proximal portion of an elongated surgical instrument and a motorized robotic surgical device.
Guidewires and microcatheters are commonly used in endovascular procedures to navigate through blood vessels. These instruments help physicians reach targeted areas and perform different medical interventions. By seeking patent protection for technology associated with connecting these instruments to a robotic device, Microbot Medical aims to protect another component of the engineering behind its LIBERTY platform.
The Canadian patent adds to the company’s existing intellectual property protections across multiple markets. Microbot Medical’s portfolio includes issued patents and pending applications covering aspects of its technology. The company is continuing to seek protection for the distinctive characteristics of LIBERTY, with the broader objective of strengthening its position as it works toward future commercialization opportunities.
Global Intellectual Property Portfolio Continues to Grow
Intellectual property protection is an important part of Microbot Medical’s long-term business strategy. Medical technology companies invest in patents to protect inventions, technical designs and innovations that may differentiate their products in competitive markets. For Microbot Medical, expanding its patent portfolio is intended to protect the technology behind its robotic surgical system and support the potential commercial value of its innovations.
The company’s reported portfolio now includes 45 issued patents and 48 patent applications worldwide. These numbers represent a combination of patents already granted and applications that remain under examination or otherwise pending. The 21 issued patents in North America form part of the broader international portfolio. The latest Canadian patent adds another granted protection to the company’s North American intellectual property position.
Building a global patent portfolio can help a technology developer establish legal protection in markets where it may seek to operate or commercialize its products. It can also help protect specific technical features from unauthorized use, subject to the scope and enforceability of each patent. For Microbot Medical, the growing portfolio is intended to safeguard the technological elements that support the LIBERTY system as the company evaluates opportunities in additional markets.
The company believes that a strong patent estate is important for supporting potential future market expansion and maximizing the value of its technology. Patent protection is one part of a wider commercialization strategy, alongside regulatory requirements, product development, market access and the establishment of appropriate business infrastructure. The latest grant therefore represents an intellectual property milestone rather than, by itself, confirmation of a new commercial launch or regulatory approval.
Company Highlights Importance of Protecting Technological Innovation
Dr. Sarit Garten, Director of Intellectual Property at Microbot Medical, emphasized that strengthening the company’s intellectual property portfolio in the United States and international markets is an important element of its strategy. She explained that protecting the company’s technological innovations is intended to support their future commercialization and provide greater confidence as Microbot Medical pursues regulatory clearances in additional markets.
The company’s strategy focuses on protecting the unique technological characteristics of its robotic platform. As medical technology developers work to introduce new products, patent protection can play a role in safeguarding the underlying inventions and supporting long-term business development. Microbot Medical is using its growing patent estate to protect innovations associated with the LIBERTY system and the components that contribute to its design and operation.
Dr. Garten also referred to the importance of international intellectual property protection as the company considers opportunities beyond its existing regulatory markets. According to the company, the strengthened patent portfolio gives it greater confidence to pursue regulatory clearances in additional countries, joining the markets where it has already obtained clearances in the United States and Israel.
This distinction is important because intellectual property protection and regulatory authorization serve different purposes. A patent protects an invention within the applicable legal framework, while regulatory clearance determines whether a medical device can be marketed for its intended use in a particular jurisdiction. The company’s announcement identifies the Canadian patent grant as an intellectual property achievement and separately notes its intention to pursue regulatory clearances in additional markets.
Understanding the LIBERTY Robotic System
LIBERTY is described by Microbot Medical as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. The platform is designed to allow physicians to remotely control the navigation of endovascular instruments. Its development is focused on supporting precision during vascular procedures while addressing some of the physical demands associated with conventional methods.
Peripheral endovascular procedures involve navigating medical instruments through blood vessels outside the heart and brain. Physicians may use guidewires and microcatheters to reach targeted areas within the vascular system. Such procedures require controlled instrument movement and careful navigation through complex anatomical pathways.
The LIBERTY system is designed to provide robotic assistance in this setting. By enabling remote operation, the platform aims to support physicians as they control instruments during procedures. The system’s design also seeks to reduce radiation exposure and physical strain, two considerations associated with certain endovascular procedures.
Radiation exposure is an important occupational consideration in image-guided medical procedures. Physicians and other healthcare professionals may work around imaging equipment during endovascular interventions, and exposure management is an important part of procedural safety. A remotely operated robotic system may help change aspects of how physicians interact with procedural equipment, although the company’s description of its intended benefits should not be interpreted as a guarantee of a specific reduction in radiation exposure for every procedure.
Physical strain is another consideration in endovascular practice. Physicians may spend extended periods performing procedures that require careful positioning and repetitive movements. Microbot Medical says LIBERTY is designed to reduce physical strain while supporting precise vascular navigation. The company is developing the platform around these intended benefits as it continues its efforts to establish a commercial presence.
Why the New Adaptor Patent Matters
The newly granted Canadian patent covers an adaptor that connects the proximal portion of an elongated surgical tool to a motorized robotic surgical device. This includes instruments such as guidewires and microcatheters. The adaptor is therefore associated with the interface between the surgical instrument and the robotic system.
In a robotic medical device, the connection between the instrument and the motorized platform is an important part of the overall design. The system must be able to interact with the instrument in a controlled manner to support the intended operation. The adaptor described in Microbot Medical’s patent relates to this connection and forms part of the company’s wider effort to protect the technical elements of its platform.
Patent protection for components and interfaces can be relevant to a medical device developer because a product’s functionality often depends on multiple interconnected technologies. Protecting individual inventions can help a company establish a broader intellectual property position around its product architecture. In Microbot Medical’s case, the Canadian patent adds to the protections it is seeking for the LIBERTY system and its associated technology.
The grant also demonstrates the company’s continued focus on international patent activity. Rather than limiting its intellectual property strategy to one market, Microbot Medical is pursuing patent protection in different jurisdictions. The company’s latest announcement indicates that it views this global approach as important to protecting its innovations and supporting potential future commercial expansion.
Patent Protection and Future Commercialization Plans
Microbot Medical’s intellectual property strategy is closely connected to its longer-term commercialization objectives. The company believes that a growing patent portfolio can help protect the value of its technology as it works to expand its presence in the medical robotics sector. Its portfolio of 45 issued patents and 48 patent applications represents the intellectual property position it has built around its innovations.
However, patent growth is only one element of bringing a medical device to market. Companies must also address regulatory requirements, manufacturing capabilities, commercial operations, physician awareness and market adoption. For a robotic medical system, these considerations can be particularly important because healthcare providers need to understand how the technology fits into existing clinical workflows and procedural environments.
Microbot Medical has stated that its intellectual property portfolio supports its efforts to pursue regulatory clearances in additional markets. The company already identifies the United States and Israel as markets where it has regulatory clearances. Its announcement does not specify new regulatory approvals resulting from the Canadian patent grant, nor does it confirm a commercialization launch in Canada. The patent should therefore be understood as an additional intellectual property achievement within the company’s broader international strategy.
The company believes that protecting its innovations can help it pursue future market opportunities with greater confidence. A strong patent portfolio may also contribute to the long-term value of a medical technology business by establishing legal protection for its inventions. Microbot Medical’s latest patent grant is consistent with this strategy as it continues to develop the infrastructure intended to support future commercialization expansion.
Expanding Its Position in Medical Robotics
The medical robotics sector continues to include technologies designed to support physicians during complex procedures. Robotic platforms are being developed for different areas of medicine, with applications that can include surgical assistance, instrument control and image-guided interventions. Microbot Medical is focused on the endovascular segment through its LIBERTY system.
The company’s approach centers on remote operation, single-use system design and vascular instrument navigation. These features distinguish the platform’s intended role in peripheral endovascular procedures. By continuing to protect its technology through patents, Microbot Medical aims to strengthen its position in this area of medical technology.
The latest patent grant in Canada adds to the company’s reported North American and international intellectual property portfolio. It also reflects the importance Microbot Medical places on protecting individual components that contribute to the operation of its robotic system. As the company continues to work toward broader commercialization, its patent strategy remains one of the foundations of its business development plans.
The Canadian Intellectual Property Office’s grant of the adaptor patent marks another step in Microbot Medical’s efforts to strengthen its global intellectual property position. With 45 issued patents and 48 patent applications worldwide, including 21 issued patents in North America, the company continues to pursue protection for the distinctive features of its LIBERTY Endovascular Robotic System.
The company views this portfolio as an important asset in protecting its technological innovations and supporting potential future market expansion. Its stated strategy also includes pursuing regulatory clearances in additional markets beyond the United States and Israel. The latest Canadian patent does not itself represent regulatory clearance or a commercial launch, but it adds to the intellectual property foundation that Microbot Medical believes will support those future objectives.
As Microbot Medical continues developing its robotic endovascular technology, the company remains focused on protecting its inventions and establishing the infrastructure needed for future commercialization. The LIBERTY system is designed to support precise vascular navigation through remote robotic operation, while aiming to reduce radiation exposure and physical strain. The new patent strengthens the company’s efforts to protect the technology behind that platform and advance its longer-term business strategy.
Source link: https://ir.microbotmedical.com/
